Curcumin C3 Complex®

What is Curcumin C3 Complex®?

Turmeric is one of the most highly regarded medicinal plants in the world. It originates from the Indian subcontinent, and today it is used globally as a dietary supplement, spice, natural food coloring, and as an ingredient in natural cosmetics.

Its popularity stems from ancient Ayurvedic medicine, which described the numerous health benefits of turmeric more than 2,500 years ago. In modern times, it is precisely modern science that has made it possible for its active compounds, especially curcumin, to be scientifically confirmed and effectively utilized.

One of the most recognized and researched extracts is Sabinsa Curcumin C3 Complex® – a patented formulation derived from the dried rhizomes of the Curcuma longa plant. This extract is standardized to a minimum of 95% curcuminoids, ensuring high potency and bioavailability.

Origin of Curcumin C3 Complex®

The source of Curcumin C3 Complex® is the most scientifically researched extract of turmeric (Curcuma longa), with over 150 scientific publications and 79 clinical studies supporting its efficacy and safety. It is a standardized extract with 95% curcuminoids that has been trusted by users worldwide for over 30 years.

Controlled production and superior quality

Sabinsa grows its turmeric on contract farms that strictly follow Good Agricultural Practices (GAP). The entire production process takes place in facilities controlled by the US FDA and is certified to the highest standards:

USP-GMP (Good Manufacturing Practice),
FSSC 22000:2005 (Food Safety).

Each batch of Curcumin C3 Complex® is rigorously tested for more than 100 types of pesticides and verified by radiocarbon analysis, confirming the 100% natural origin of the ingredients.

Verified Purity and Safety

This unique turmeric extract boasts internationally recognized certifications:

TRU-ID – confirms the authenticity of plant ingredients,
Non-GMO Verified – free of genetically modified organisms,
GRAS status – officially recognized as safe by the US FDA.

Awarded and recognized worldwide

Curcumin C3 Complex® has received numerous prestigious awards, including:

Scientific Achievement Award (NBJ, 2007),
Product Merit Award (NBJ, 2008),
Marketing Excellence Award (Functional Ingredients, 2012),
NutraIngredients-USA Award (2016).

How does Curcumin C3 Complex® affect our health?

Curcumin and related curcuminoids, the natural active compounds in the turmeric plant (Curcuma longa), have numerous scientifically supported health benefits.

What results have the scientific studies shown about Curcumin C3 Complex® shown?

Below are the main results from various clinical studies on Curcumin C3 Complex®:

1. Support for COVID-19 (mild to moderate disease) (1)

Study: Open, unstructured clinical study in hospitalized patients with COVID-19.
Findings: Consumption of nano-curcumin accelerated the disappearance of symptoms (fever, cough, muscle pain), improved oxygen saturation and reduced the length of hospital stay. None of the patients in the curcumin group experienced a worsening of the disease, which occurred in 40% of the control group.
Conclusion: Curcumin C3 can support a faster recovery in patients with COVID-19 without side effects.

2. Reducing Inflammation and Oxidative Stress in Severe Head Injury (2)

Study: Randomized, double-blind, placebo-controlled trial.
Findings: Curcuminoids significantly reduced inflammatory biomarkers (IL-6, TNF-α, CRP) and improved clinical outcomes and nutritional status of patients.
Conclusion: Short-term supplementation with Curcumin can significantly reduce inflammation and support recovery in critically ill patients with head injury.

3. Improvement of symptoms of functional dyspepsia (3)

Study: Randomized, triple-blind, placebo-controlled trial.
Findings: The combination of curcumin and famotidine reduced symptoms of dyspepsia and reduced the prevalence of Helicobacter pylori infection.
Conclusion: Curcumin C3 can effectively improve digestive problems and reduce chronic inflammation of the gastric mucosa.

4. Effects on adipokines in critically ill patients with TBI (4)

Study: Randomized, double-blind, placebo-controlled.
Findings: Curcuminoid supplementation reduced leptin levels, which are associated with inflammation, while not affecting adiponectin.
Conclusion: Curcumin C3 contributes to the regulation of inflammation and metabolic markers in critically ill patients.

5. Reducing inflammation in nonalcoholic fatty liver disease (NAFLD) (5)

Studies: Randomized, double-blind, placebo-controlled trial.
Findings: Curcuminoids reduced body weight, improved liver ultrasound appearance, and reduced inflammatory cytokines such as TNF-α and MCP-1.
Conclusion: Curcumin C3 supports liver health by reducing inflammation and fatty changes.

6. Antioxidant effects in patients with renal failure and type 2 diabetes (6)

Study: Randomized controlled trial.
Findings: Supplementation of 2000 mg Curcumin C3 significantly increased the antioxidant capacity of the blood and contributed to the successful maturation of arteriovenous fistula in dialysis patients.
Conclusion: Curcumin C3 plays an important role in protecting the vascular system and improving health in patients with kidney disease.

Legal notice

Curcumin C3 Complex®, an ingredient marketed by Sabinsa Corporation, is intended for inclusion in food products or food supplements by specialized companies. As such, the information provided on this page is intended specifically for them. In accordance with the requirements of European Directive 2006/114/EC, Sabinsa Corporation guarantees the veracity of the information regarding the beneficial effects of Curcumin C3 Complex® on health when used under the conditions in which it was tested. However, this does not in any way exempt those who place on the market foods and food supplements containing Naticol® from verifying the veracity of these claims when used in their products. In addition, European Regulation 1924/2006/EC regulates the use of nutrition and health claims on foods intended for the final consumer. Claims related to the health benefits of Curcumin C3 Complex®, as mentioned on this page, are therefore not covered by the requirements of this Regulation. This information has not been evaluated by the Food and Medicines Agency and therefore does not constitute health claims approved by EFSA.

📚 Source of information and literature

Shafiee A. et al.Curcumin for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials. Phytother Res. 2023;37(3):1167–1175. PMID:36640146
Abdolahi M. et al.The effects of curcuminoids on inflammatory markers in traumatic brain injury: randomized double-blind trial. Phytother Res. 2020. PMID:32291880
Bundhun PK. et al.Curcumin and famotidine in functional dyspepsia: a randomized triple-blind placebo-controlled trial. Clin Transl Gastroenterol. 2021. PMID:34115936
Asghari Jafarabadi M. et al.Curcuminoids supplementation and adipokines in traumatic brain injury patients: randomized controlled trial. J Diet Suppl. 2020. PMID:32814477
Panahi Y. et al.Curcuminoids in non-alcoholic fatty liver disease: randomized double-blind placebo-controlled trial. Phytother Res. 2017;31(12):1907–1914. PMID:28921839
Khajehdehi P. et al.Curcumin improves oxidative stress and vascular function in hemodialysis patients with type 2 diabetes. Clin Nutr. 2011;30(4):475–480. PMID:21493055
Clinical Evidence – Curcumin C3 Complex (selection of clinical RCTs and trials). curcuminoids.com/clinical-evidence

📚Pharmacology & Clinical Trials

8. Curcumin/Piperine - IND study approved: IND# 61,872
Food & Drug Administration Office of Drug Evaluation I, Division of Oncology Drug Products
9. The effects of Curcuminoids on aberrant crypt foci in the human colon: IND# 51,685
UMDNJ - Robert Wood Johnson Medical School, New Jersey Cancer Institute
10. Pilot study of curcuminoids with or without BioPerine® in patients with multiple myeloma: IND# 67,963
MD Anderson Cancer Center, University of Texas
11. Prevention and intervention of Alzheimer's disease with curcuminoids
University of California, Los Angeles
12. Curcuminoids in patients with Lichen planus: IND#65,700/S-000
University of California
13. Phase IIa prevention study of C3 Complex®curcuminoids in women at increased risk for breast cancer
MD Anderson Cancer Center, University of Texas
14. The clinical and laboratory effects of topical curcuminoids in patients with normal skin and with dysplastic and benign nevi
National Cancer Institute
15. Phase II prevention study with C3 Complex® in patients with colorectal cancer stage I-III
Lincoln Medical and Mental Health Center, Bronx, NY
16. Phase I trial of C3 Complex® and precooperative patients with locally advanced esophageal or gastroesophageal carcinoma
MD Anderson Cancer Center, University of Texas
17. Metabolic studies and chemopreventive studies
University of Leicester, UK